FDAnews
www.fdanews.com/articles/146507-dendreon-rsquo-s-provenge-works-best-for-patients-with-low-psa-scientists-say

Dendreon’s Provenge Works Best for Patients With Low PSA, Scientists Say

May 17, 2012
From the moment Dendreon started in business 20 years ago, most scientists have said that if its immune-booster for prostate cancer was going to work, it would probably work best at an early stage of disease, before tumors had gotten too powerful for the immune system to contain. Today, Dendreon is offering the latest slice of data that suggests that may be the case.
Xconomy